Safety and effectiveness of bis-chloroethylnitrosourea wafer chemotherapy in elderly patients with recurrent glioblastoma

• Verfasst von: Klein, Johann [VerfasserIn]
• Verfasst von: Juratli, Tareq [VerfasserIn]
• Verfasst von: Radev, Yordan Todorov [VerfasserIn]
• Titel: Safety and effectiveness of bis-chloroethylnitrosourea wafer chemotherapy in elderly patients with recurrent glioblastoma
• Verf.angabe: Johann Klein, Tareq A. Juratli, Yordan Radev, Dirk Daubner, Silke Soucek, Gabriele Schackert, Dietmar Krex
• E-Jahr: 2017
• Jahr: April 11, 2017
• Umfang: 8 S.
• Teil: volume:93
• Teil: year:2017
• Teil: number:1
• Teil: pages:43-50
• Teil: extent:8
• Fussnoten: Gesehen am 25.10.2018
• Titel Quelle: Enthalten in: Oncology
• Ort Quelle: Basel : Karger, 1967
• Jahr Quelle: 2017
• Band/Heft Quelle: 93(2017), 1, Seite 43-50
• ISSN Quelle: 1423-0232
• DOI: doi:10.1159/000464464
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1582282528

Abstract

<b><i>Objective:</i></b> To assess the safety and effectiveness of bis-chloroethylnitrosourea (BCNU) wafers in elderly patients with recurrent glioblastoma (GBM). <b><i>Methods:</i></b> Patients with recurrent GBM operated on between 2007 and 2014 were divided into 3 groups: >65 years with BCNU wafer implantation, >65 years without BCNU wafer implantation, and ≤65 years with BCNU wafer implantation. We compared survival and complications. <b><i>Results:</i></b> A total of 79 patients were identified: 24 in the older BCNU group (median age 68.2 years, 33.3% with a methylated <i>MGMT</i> promoter), 16 in the older non-BCNU group (median age 68.6 years, 31.3% with a methylated <i>MGMT</i> promoter), and 39 in the younger BCNU group (median age 56.8 years). Survival after progression was 9.2 months in the elderly BCNU group and 7.6 months in the elderly non-BCNU group (<i>p</i> = 0.34); overall survival was 17.2 and 15.9 months, respectively (<i>p</i> = 0.35). We found a tendency toward a higher rate of seizures and pneumonia in the older BCNU group. <b><i>Conclusion:</i></b> BCNU wafer implantation after resection of recurrent GBM is a reasonably safe treatment in patients aged >65 years. Seizures and systemic infections may occur more frequently, but the trade-off is still favorable as survival may be influenced positively. Higher age should not be regarded as a contraindication for BCNU wafers.